A Long-Term, Open-Label, Multicenter Study of LY2140023 Compared to Atypical Antipsychotic Standard of Care in Patients With DSM-IV-TR Schizophrenia.

Trial Profile

A Long-Term, Open-Label, Multicenter Study of LY2140023 Compared to Atypical Antipsychotic Standard of Care in Patients With DSM-IV-TR Schizophrenia.

Discontinued
Phase of Trial: Phase II/III

Latest Information Update: 20 May 2016

At a glance

  • Drugs Pomaglumetad methionil (Primary) ; Aripiprazole; Olanzapine; Quetiapine; Risperidone
  • Indications Schizophrenia
  • Focus Adverse reactions
  • Sponsors Eli Lilly
  • Most Recent Events

    • 06 Feb 2014 New source identified and integrated (Clinical Research Information Service (CriS)-Republic of Korea)
    • 29 Aug 2012 Status changed from recruiting to discontinued, according to an Eli Lilly media release.
    • 19 May 2012 This study has been completed in Germany, according to the European Clinical Trials Database record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top